Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment-Reference-Cited by-同舟云学术

Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment

Published:2018-08-23 Issue:8 Volume:132 Page:825-836
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cader Fathima Zumla¹^ORCID,Schackmann Ron C. J.²,Hu Xihao³⁴^ORCID,Wienand Kirsty¹^ORCID,Redd Robert³⁴,Chapuy Bjoern¹,Ouyang Jing¹,Paul Nicole⁵,Gjini Evisa⁶,Lipschitz Mikel⁶,Armand Philippe¹,Wu David⁷^ORCID,Fromm Jonathan R.⁷,Neuberg Donna³⁴^ORCID,Liu X. Shirley³⁴,Rodig Scott J.⁶^ORCID,Shipp Margaret A.¹^ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Cell Biology, Harvard Medical School, Boston, MA;

3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;

4. Harvard T.H. Chan School of Public Health, Boston, MA;

5. Longwood Medical Area CyTOF Core Facility, Dana-Farber Cancer Institute, Boston, MA;

6. Department of Pathology, Brigham and Women’s Hospital, Boston, MA; and

7. Department of Pathology, University of Washington, Seattle, WA

Abstract

Key Points Newly diagnosed primary cHLs have a concomitant increase in CD4+ Th1-polarized Tregs and differentiated Teffs. Primary cHLs exhibit 2 major complementary bases of immunosuppression: likely exhausted PD-1+ Th1 Teffs and active PD-1− Th1 Tregs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/8/825/1467258/blood843714.pdf

Reference58 articles.

1. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma;Green;Blood,2010

2. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome;Roemer;J Clin Oncol,2016

3. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma;Roemer;J Clin Oncol,2018

4. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma;Ansell;N Engl J Med,2015

5. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial;Armand;J Clin Oncol,2018

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma;Scientific Reports;2024-01-06

2. Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment;Best Practice & Research Clinical Haematology;2023-12

3. Checkpoint inhibition in hematologic malignancies;Frontiers in Oncology;2023-10-17

4. SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-10

5. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy;Cancers;2023-09-11